Association of Autoantibodies against M2-Muscarinic Acetylcholine Receptor with Atrial Fibrosis in Atrial Fibrillation Patients
Table 1
Baseline characteristics of the control group and study population.
Control group (n = 25)
AF group (n = 24)
Non-AF group (n = 26)
Clinical parameters
Age (years)
65.6 ± 7.8
62.5 ± 9.9
65.8 ± 7.3
Gender, male (%)
13 (52.0)
16 (66.7)
14 (53.8)
Smoking (%)
9 (36.0)
9 (37.5)
10 (38.5)
Alcohol consumption (%)
7 (28.0)
8 (33.3)
8 (30.8)
BMI (kg/m2)
25.4 ± 2.9
26.6 ± 3.8
25.7 ± 3.1
Comorbidity
Hypertension (%)
0
12 (50.0)
14 (53.8)
Diabetes mellitus (%)
0
9 (37.5)
10 (38.5)
History of stroke (%)
0
10 (41.7)
11 (42.3)
Echocardiographic parameters
Left atrium diameter (mm)
36.0 ± 1.2
58.0 ± 5.3
36.3 ± 1.1
LVEDD (mm)
48.9 ± 1.8
50.0 ± 3.3
49.2 ± 2.0
LVEF (%)
62.4 ± 4.3
60.3 ± 8.6
62.1 ± 5.0
Pulmonary function
FEV1 (L)
2.8 ± 0.5
2.6 ± 0.4
2.6 ± 0.2
FEV1/FVC (%)
77.6 ± 2.8
76.6 ± 4.1
76.8 ± 3.6
BMI, body mass index; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; Anti-M2-R, autoantibodies against M2-muscarinic acetylcholine receptors. One-way ANOVA and the unpaired Student’s two-tailed t-test were performed among the three groups or between two groups. .
